Literature DB >> 21430338

A brief history of antiretroviral therapy of HIV infection: success and challenges.

Lucia Palmisano1, Stefano Vella.   

Abstract

Unprecedented efforts in the fields of biology, pharmacology and clinical care have contributed to progressively turn HIV infection from an inevitably fatal condition into a chronic manageable disease, at least in the countries where HIV infected people have full access to the potent antiretroviral drug combinations that allow a marked and sustained control of viral replication. However, since currently used treatments are unable to eradicate HIV from infected individuals, therapy must be lifelong, with the potential for short- and long-term, known and unknown, side effects, and high costs for health care systems. In addition, different patterns of unexpected systemic complications involving heart, bone, kidney and other organs are emerging. Although their pathogenesis is still under debate, they are likely to originate from chronic inflammation and immune dysfunction associated to HIV infection. A final consideration regards the dishomogenous pattern of HIV disease worldwide. In fact, access to HIV diagnosis, treatment and care are seriously limited in the geographical areas that are most affected, like Africa, which sustains 70% of the global burden of the infection. This is one of the greatest challenges that international institutions are asked to face today.

Entities:  

Mesh:

Year:  2011        PMID: 21430338     DOI: 10.4415/ANN_11_01_10

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  41 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

Review 2.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

Review 3.  Who will develop new antibacterial agents?

Authors:  Stewart T Cole
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

4.  Optimal control therapy and vaccination for special HIV-1 model with delay.

Authors:  Elham Shamsara; Jamal Shamsara; Zahra Afsharnezhad
Journal:  Theory Biosci       Date:  2016-08-03       Impact factor: 1.919

Review 5.  Social determinants of adult sex ratios and racial/ethnic disparities in transmission of HIV and other sexually transmitted infections in the USA.

Authors:  Enrique Rodriguez Pouget
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-09-19       Impact factor: 6.237

6.  An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.

Authors:  Zainab K Sanusi; Thavendran Govender; Glenn E M Maguire; Sibusiso B Maseko; Johnson Lin; Hendrik G Kruger; Bahareh Honarparvar
Journal:  J Comput Aided Mol Des       Date:  2018-02-03       Impact factor: 3.686

7.  Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals.

Authors:  Aiping Qin; Weiping Cai; Ting Pan; Kang Wu; Qiong Yang; Nina Wang; Yufeng Liu; Dehong Yan; Fengyu Hu; Pengle Guo; Xiaoping Chen; Ling Chen; Hui Zhang; Xiaoping Tang; Jie Zhou
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 8.  Nano-ART and NeuroAIDS.

Authors:  Malay K Das; Anupam Sarma; Tapash Chakraborty
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 9.  HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.

Authors:  Paul Spearman
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 10.  Antiretroviral medication: an emerging category of prescription drug misuse.

Authors:  Glen P Davis; Hilary L Surratt; Frances R Levin; Carlos Blanco
Journal:  Am J Addict       Date:  2013-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.